Morphology of the corpus callosum at different stages of schizophrenia: cross-sectional study in first-episode and chronic illness


Background
The shape of the corpus callosum may differ in schizophrenia, although no study has compared first-episode with established illness.

Aims
To investigate the size and shape of the corpus callosum in a large sample of people with first-episode and established schizophrenia.

Method
Callosal size and shape were determined using high-resolution magnetic resonance imaging on 76 patients with first-episode schizophrenia-spectrum disorders, 86 patients with established schizophrenia and 55 healthy participants.

Results
There were no significant differences in total area across groups. Reductions in callosal width were seen in the region of the anterior genu in first-episode disorder (P<0.005). Similar reductions were seen in the chronic schizophrenia group in the anterior genu, but also in the posterior genu and isthmus (P=0.0005).

Conclusions
Reductions in anterior callosal regions connecting frontal cortex are present at the onset of schizophrenia, and in established illness are accompanied by changes in other regions of the callosum connecting cingulate, temporal and parietal cortices.

Declaration of interest
None. Funding detailed in Acknowledgements.

The corpus callosum has been strongly implicated as an anatomical mediator of dysfunctional inter-hemispheric transfer in schizophrenia, and anomalies of the corpus callosum are found more commonly in people with schizophrenia than the general population. The first magnetic resonance imaging (MRI) study suggested alterations in its size and shape in schizophrenia. Subsequent analyses have found conflicting results, including global increases, reductions or no differences compared with healthy individuals, although a meta-analysis of the first decade of studies suggests this structure is smaller in patients than in controls. Data from people experiencing their first episode of schizophrenia suggest that the corpus callosum may also be smaller than in healthy individuals.

The aim of the present MRI study was to determine whether the measures of callosal size and shape in a large cohort (n=217) of individuals across differing illness stages (first-episode schizophrenia-spectrum disorders and established illness) differed from that of controls. Based on previous work we hypothesised that patients with established illness would show a globally smaller corpus callosum and reductions in regions connecting frontal and temporal regions, with patients with first-episode schizophrenia-spectrum disorders exhibiting similar reductions.

Method
Participants
All participants with first-episode schizophrenia-spectrum disorders, aged between 16 and 30 years, were recruited from the Early Psychosis Prevention and Intervention Centre (EPPIC; n=76) and participants with chronic schizophrenia from inpatient and community mental health settings (n=86) within the North Western Mental Health Program, Melbourne, Australia. The DSM–III–R diagnoses were based on chart review and structured diagnostic interviews. Control participants (n=55) from similar socio-demographic areas as the patients were recruited from ancillary hospital staff and through advertisements. Demographic data were obtained for all participants (see online data supplement Table DS1). Inclusion criteria for participants in the first-episode schizophrenia-spectrum group (‘first-episode group’, which included patients with schizophrenia (n=30), schizoaffective disorder (n=15), established illness group and for controls, recruited from 1994 to 1999, have been previously described. Patients in the established illness and first-episode groups were rated on the Positive and Negative Syndrome Scale (PANSS) by trained raters, and medication at the time of scanning was converted to chlorpromazine equivalents.

Participants were screened for comorbid medical and psychiatric conditions by clinical assessment, and physical and neurological examination. Written informed consent was obtained from all participants. The study was approved by the local Research and Ethics Committee. Exclusion criteria for patients were: a history of significant head injury, seizures, neurological diseases, impaired thyroid function, steroid use or DSM–III–R criteria of alcohol or substance dependence. Controls with a personal history of psychiatric illness or family history of psychosis were excluded.

Magnetic resonance scanning acquisition and analysis
All participants were scanned on a 1.5 T GE Signa MRI machine. A three-dimensional volumetric spoiled gradient recalled echo in the steady state sequence generated 124 contiguous, 1.5 mm coronal slices. Imaging parameters were: time-to-echo (TE), 3.3 ms; time-to-repetition (TR), 14.3 ms; flip angle, 30°; matrix size, 256 × 256; field of view (FOV), 24 × 24 cm matrix; voxel...
dimensions, 0.938 × 0.938 × 1.5 mm. Head movement was minimised by foam padding and straps across the forehead and chin. This scanner was calibrated fortnightly using the same proprietary head. Using the software package Automated Image Registration (Red Hat Linux V9), images were registered to a template image comprising the average of 152 normal T1-weighted MRI scans previously placed in stereotaxic coordinate space. A nine-parameter linear transformation was used which allowed translation, rotation and scaling along each of the three principal axes. The midsagittal slice was identified and interpolated to a voxel dimension of 0.5 mm × 0.5 mm in the y- and z-planes. White matter voxels in the midsagittal slice were identified using a histogram segmentation procedure. Non-callosal voxels were then removed manually. A measure of callosal area in total mm2 was then generated. To measure regional callosal thickness, voxels at the edge of the callosum were identified, and upper and lower edges were defined according to anterior and posterior endpoints. An iterative search for optimum endpoints which maximised the length of a line segment traversing the centre of the callosum was then performed (Fig. 1). The line segment was defined by dividing the upper and lower surfaces of the callosum into 40 equidistant portions by 39 nodes. The midpoints between corresponding nodes on the upper and lower surfaces were identified. The line segment was created by joining endpoints and successive midpoints. Once the optimum endpoints and corresponding midpoints were identified, a smooth curve joining them was obtained with cubic spline interpolation. This curve was divided into 40 segments of equal lengths by 39 nodes. At each node, the line orthogonal to the curve was calculated. The distance between its intersection with the dorsal and ventral surfaces of the callosum represented the curve was calculated.

Endpoints, midpoint and dividing nodes used to measure callosal thickness.

Fig. 1

Statistical analysis

Five analyses were undertaken on the four callosal measures of total callosal area and regional callosal thickness:

(a) comparison of main patient groups: first-episode, established illness and controls
(b) comparison of first-episode psychosis subgroups and controls
(c) analysis of effect of age on patients with established illness and controls, and duration of illness on patients with established illness
(d) analysis of the relationship between medication and callosal measures.
(e) analysis of the relationship between psychotic symptoms and callosal measures.

Determination of the effects of demographic variables was undertaken with chi-square analyses for gender and one-way analysis of variance (ANOVA) with Tukey’s post hoc comparison for age in years, height in centimetres and premorbid IQ measured using the National Adult Reading Test. Positive and negative symptom scales on the PANSS were compared using ANOVA for three-group comparisons and t-tests for two-group comparisons. Callosal area was compared between groups using ANOVA. For regional callosal thickness, a non-parametric permutation method of 10 000 randomisations was used for group comparisons to account for non-independence between adjacent thickness measurements and for multiple comparisons; step-down tests were used to localise at which slices the thickness differed significantly. Two-group comparisons were undertaken with t-tests, and localisation for individual slice differences again using step-down testing. Non-parametric regression analyses using multiple dependent variables were undertaken to determine the effect of medication dose and positive and negative symptoms on callosal thickness measures. Statistical inference was based on the family-wise error rate method to correct for multiple comparisons.

Results

Demographic and illness data

Comparison of the established illness, first-episode and control groups (see online Table DS1) demonstrated significant differences in gender (χ²=9.68, P<0.01) with an excess of males with established illness compared with other groups, and age (F(2,216)=53.80, P<0.001) with first-episode<controls<established illness. Premorbid IQ differed significantly across groups (F(2,216)=6.48, P<0.005) with controls>first-episode>established illness. There were no significant differences across groups in handedness (χ²=5.13, P=0.274) or height (F(2,216)=0.188, P=0.829). Mean duration of illness prior to first scan in the established illness group was 13.30 years (s.d.=8.95), and in the first-episode group the duration of their index psychotic episode prior to first scan was 64.20 days (s.d.=112.22). The age at onset of psychosis did not differ between the two broad patient groups (t=1.264, P=0.208). The PANSS negative symptom total score was higher in the established illness group at a trend level (t=1.741, P=0.084), although positive symptoms did not differ (t=−1.634, P=0.105). Medication dosage was significantly higher in the established illness group (t=7.346, P<0.0001). When the three first-episode groups were compared, there were no significant differences on any demographic, medication, illness onset/duration variables or symptom variables, other than PANSS positive symptoms which were lower in the first-episode schizophrenia group (F(2,23)=6.683, P=0.002).

Analysis 1: main groups

Total area of the corpus callosum did not differ significantly between the three main groups (F(2,216)=1.094, P=0.337), nor when analyses were limited to males and right-handers. Illness duration was not associated with area in the established illness group (r=−0.052, P=0.638). Females across the sample had larger callosal area (675.94 mm²) than males (648.76 mm²), although this did not reach significance (P=0.076). A significant group × gender effect was found (F(2,216)=3.238, P=0.041) with females (715.44 mm²) having a significantly larger total area than males (640.70 mm²) only in the control group (F(1,54)=6.028, P<0.05). When left-, right- and mixed-handed groups were
examined, corpus callosal area did not differ overall ($F_{2,216}=0.710, P=0.493$), although a significant group $\times$ handedness effect was found ($F_{6,216}=3.335, P=0.038$). Although in the control group left-handed people had a larger callosal area than right-handed people, this difference was not seen in the patient groups. There was no gender $\times$ handedness effect (by group) on area. Group differences were apparent in the length ($F_{2,216}=3.844, P=0.023$), curvature ($F_{2,216}=6.871, P=0.001$) and mean width ($F_{2,216}=3.685, P=0.026$) of the callosum however, with patients with established illness having longer, thinner and more angulated callosi than the other two groups, which were comparable.

When comparing regional callosal thickness across groups, a number of differences were found. Across the three main groups (Fig. 2), a main effect of group was found ($P<0.0001$) at slices 1–5 (anterior genu) and 29–30 (isthmus) which remained significant when age was controlled for ($P<0.05$) or when only males were analysed ($P<0.001$). In step-down comparisons, significantly smaller widths were seen in the established illness group compared with the control group at slices 1–5, 11–21 and 28–30 ($P=0.0005$); and in the first-episode group as a whole at slices 1–3 ($P<0.005$). Identical regional changes were seen in the male only cohort.

To examine differences in corpus callosal thickness across illness stages, the two patient groups (first-episode and established illness) were compared. When the established illness group was compared with the first-episode group, the established illness group had significantly smaller widths in slices 13–17 and 27–32 ($P<0.05$).

Analysis 2: first-episode subgroups

The three first-episode subgroups did not differ significantly on measures of callosal area ($F_{2,75}=1.429, P=0.246$), curvature ($F_{2,75}=1.927, P=0.153$), length ($F_{2,75}=0.103, P=0.902$) and mean thickness ($F_{2,75}=1.690, P=0.192$). When regional callosal thickness was compared between groups, there was no overall effect of group (Fig. 3, $P=0.145$). When first-episode subgroups were compared with the control group, only when the schizophrenia group was compared was an effect of group found ($P<0.05$), with significant reductions seen in slices 3 and 4, located in the genu of the callosum; the schizoaffective group comparison, equally well-powered, showed no overall effect of group ($P=0.638$). Interestingly, the schizoaffective disorder group showed a trend ($P=0.079$) towards a group effect with a reduction seen in slice 3, and exploratory post hoc analyses suggested significant ($P<0.05$) increases in slices 25–27 and 36–39, when compared with the control group.

Analysis 3: age and duration of illness variables

As previous authors had found a loss of age-related expansion of callosal area in people with first-episode schizophrenia, the relationship of age to callosal area was examined separately in each group (Fig. 4). This relationship was seen in the control group ($r=0.297, P<0.05$), but not in the established illness group ($r=−0.050, P=0.648$), and this difference was significant ($P<0.05$); the first-episode group’s narrow age range prevented meaningful comparisons.

When callosal shape was investigated through examination of callosal slice thickness, no age $\times$ group interaction was found ($P=0.232$). When examining the effect of age on regional callosal thickness, in the healthy control sample, an expansion was seen in nodes 38 and 39 with age ($P<0.05$), not seen in the established illness group. However, the established illness group showed a reduction with age in nodes 30–32 ($P<0.01$); of note, a trend towards an effect of duration of illness was seen in this region, in nodes 30–31 ($P=0.078$).

Analysis 4: medication dosage

Complete medication data at scanning time were available for 66/86 patients with established illness (28 on typical and 36 on atypical antipsychotics and 2 on no medication) and for 72/76 patients with first-episode schizophrenia-spectrum disorders (27 on typicals, 43 on atypicals and 2 on no medication). There was no difference in any demographic measure (age/gender/height/premorbid IQ) between those on typical v. atypical antipsychotics, and no difference in the main callosal measures (area, length, curvature and thickness) across and within the established illness and first-episode groups. Removing patients on lithium treatment ($n=3$) did not affect the results.

Medication dosage in chlorpromazine equivalents did not affect any of the main callosal measures, although it negatively correlated with curvature alone ($r=−0.357, P=0.007$) in the first-episode group. In the regression analysis, medication dose was not significantly related to regional slice thickness in the first-episode or established illness groups.
Analysis 5: symptoms

In the patient group (established illness and first-episode schizophrenia-spectrum disorders) as a whole, positive symptoms on the PANSS did not correlate with any callosal variable whereas negative symptoms significantly negatively correlated with callosal bending angle ($r=-0.215$, $P=0.013$). In the established illness group alone, neither positive nor negative symptoms correlated with any callosal variable; in the first-episode group, a positive correlation was demonstrated between negative symptoms and callosal area ($r=0.307$, $P=0.018$) and thickness ($r=0.288$, $P=0.027$). Regression analysis showed no relationship between positive or negative symptoms in either patient group.

Discussion

We used a novel method to examine the size and shape of the corpus callosum in a large sample of patients with psychosis and schizophrenia across varying stages of illness. Additionally, this study is unique in comparing individuals at two illness stages (first psychotic episode and established psychosis) with healthy controls. This study has identified that callosal morphological changes are greatest in those patients with chronic schizophrenia. The anterior corpus callosum changes in patients with first-episode schizophrenia-spectrum psychosis suggest that changes seen in patients with chronic schizophrenia are present in the early stages of illness, as the reductions present in the genu in both patient groups were not seen in controls. These findings suggest that anatomical changes in the anterior callosum are present at the time of the first episode, and further changes develop in non-genu regions with progression of illness – or that the subgroup of patients with first-episode psychosis who develop chronic illness may have additional changes not seen in those who do not progress. These changes appear to be independent of medication, and independent of positive symptoms, although negative symptoms at first episode did show an unexpected positive relationship with total callosal size and mean thickness that was not present in established illness.

Regional thickness changes

Regional thickness of the corpus callosum has not been examined in other cohorts using a method like that described in this study. The most similar method of analysis was a study by Downhill et al., comparing controls, patients with schizophrenia and patients with schizotypal personality disorder, dividing the callosum into 30 segmental areas (not widths) based on equidistant nodes along a mid-callosal spline and using repeated-measures ANOVA. This study found a smaller area in both the genu and splenium of patients with schizophrenia; findings in the genu are consistent with our findings. Their research did not assess a first-episode group but did include a schizotypy comparator group. The advantage of using computational morphometry is that it avoids the arbitrary distinction of the corpus callosum into defined subregions, such as the method defined by Witelson, and ensures that the methodology is free of arbitrary anatomical assumptions that may alter the results. Additionally, a methodology that uses a large number of subdivisions or slices increases the potential of detecting subtle regional changes, and rigorous non-parametric methods for statistical inference allow correction for multiple comparisons and dependence of adjacent slice measurements.

Changes at illness stage

In addition, no other study has examined callosal morphology using patients with first-episode psychosis/schizophrenia or chronic schizophrenia using the same methodology. As the findings in patients with first-episode schizophrenia-spectrum disorders and with established illness were homologous in anterior regions, a similar process may be involved in causing the regional reductions in the genu of the corpus callosum in both groups, indicating that anterior pathology is present at first episode of illness. Chronic schizophrenia shows similar reductions in the anterior genu (slices 2–5, carrying ventral/medial prefrontal fibres), with additional reductions in posterior genu/anterior body (slices 13–17, carrying cingulate, premotor and supplementary motor area fibres) and isthmus (slices 27–32, carrying cingulate, superior temporal and posterior parietal fibres). It may be these changes outside the anterior genu that are related to a subgroup who develop chronic illness, whereas changes in the genu that occur with or prior to first episode of psychosis may reflect an earlier neurodevelopmental insult present across subgroups, or changes that occur during first psychosis. A second possibility is that these changes represent illness progression; however, longitudinal analysis in the same individuals is needed to demonstrate the presence of ‘neuroprogressive’ change conclusively. Examining individuals pre-psychosis who later progress to psychosis would allow a determination of the timing of the onset of these changes.

The subgroup analysis of the first-episode group identified anterior reductions in the schizophrenia and schizoaffective disorder subgroups, but not the schizophreniaform subgroup. Assuming that the schizophreniaform subgroup differs from the schizophrenia subgroup only in duration of symptoms, this raises the possibility that the genual changes seen actually occur during the first psychotic episode rather than prior to it. Furthermore, since only the schizoaffective disorder subgroup showed expansions in other callosal regions, the results may suggest that the affective axis of this illness is associated with changes in other brain regions. We also mirrored the results of Keshavan et al. in showing a loss of the normal age-related expansion of corpus
callosal area in schizophrenia, although this finding contrasts with that of Woodruff et al, who showed a loss of the negative correlation between age and corpus callosal area in patients. The corpus callosus is topographically organised, with anterior segments connecting anterior cortical regions and posterior segments connecting posterior cortical regions. In Alzheimer’s disease, patients with dementia and in the pre-dementia phase show reductions in callosal regions associated with cortical hypometabolism and atrophy; it could be that alterations in cortical regions seen in schizophrenia in prefrontal, temporal and inferior parietal cortex would be associated with regional changes in the callosal genu, isthmus and anterior splenium. Shape analysis of the corpus callosus has implicated these regions in patients with first-episode schizophrenia. This suggests that not only are these changes present at the first episode of schizophrenia and thus potentially representative of neurodevelopmental changes, but that they may relate to grey matter changes – although studies examining both cortical regions and callosal subregions are lacking. Previous studies of the corpus callosus in schizophrenia have been limited by small sample sizes (the mean number of patients was 25 and of controls was 17 in studies prior to Woodruff’s 1995 meta-analysis) and many studies have not controlled for factors known to affect corpus callosal size and shape, including gender, handedness and age. In addition, as antipsychotic medication has been shown to produce increases and decreases in regional white matter volume and may confound longitudinal studies or those that aim to compare individuals at different illness stages, the possible effect of medication is an important potential confounder on corpus callosum structure, not yet examined in morphometry studies. Examining patients across the life-cycle of schizophrenia may shed light on the neurodevelopmental timing of a potential neuropathological process and may provide insights about the relationship of brain changes to prognosis.

Relevance of white matter changes

This study leaves a number of unanswered questions. The first of these is whether callosal changes are primary or secondary to grey matter changes that have been reported in studies of individuals who are pre- or peri-psychotic. A compelling body of neuroimaging evidence exists implicating white matter structures, including the corpus callosum, in schizophrenia, and callosal volume, have been reported for fibre numbers in the corpus callosum in healthy individuals and in people with schizophrenia. Some evidence for an alternative explanation (that reduced callosal size is secondary to reduced myelination) comes from studies examining signal intensity in callosal white matter, an index of myelination; reduced signal intensity has been shown in schizophrenia and bipolar disorder, but not in major depression or other psychiatric disorders. Thus, one explanation for our findings is an interaction between the development of psychotic illness and normal neurodevelopment on corpus callosum fibre number and/or myelination.

Conclusions

Our findings suggest that the corpus callosum in schizophrenia differs significantly in shape from that in healthy individuals, and that some of these changes are present or occur during the first episode of psychosis. The relationship between findings of changes in white matter regions that connect grey matter structures previously demonstrated to show neuropathological and volumetric change in schizophrenia is intriguing, but these findings alone do not allow elucidation of which of these pathologies may be primary, or whether they occur in concert. Longitudinal studies that elucidate the temporal relationship between white and grey matter change are necessary to shed light on causal relationships, if any, between changes in these two compartments of the central nervous system in schizophrenia.

Mark Walterfang, FRANZCP, Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, and North Western Mental Health Program, Sunshine Hospital and Royal Melbourne Hospital, Melbourne; Amanda G. Wood, PhD, David C. Reutens, MD, FRACP, Department of Medicine (Neuropsychiatries), Southern Clinical School, Monash University, Melbourne; Stephen J. Wood, PhD, Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, and North Western Mental Health Program, Sunshine Hospital and Royal Melbourne Hospital, Jian Chen, ME, Department of Medicine (Neuropsychiatries), Southern Clinical School, Monash University, Melbourne; Dennis Velakoulis, FRANZCP, Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, and North Western Mental Health Program, Sunshine Hospital and Royal Melbourne Hospital; Patrick D. McGorry, FRANZCP, ORYGEN Research Centre, Early Psychosis Prevention and Intervention Centre (EPPIC), Personal Assistance and Crisis Evaluation (PACE) Clinic, and Department of Psychiatry, University of Melbourne; Christos Pantelis, MD, FRANZCP, Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, and North Western Mental Health Program, Sunshine Hospital and Royal Melbourne Hospital, Melbourne, Australia.

Correspondence: Mark Walterfang, Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Melbourne, VIC 3050, Australia. Email: mark.walterfang@mh.org.au

First received 7 Jun 2007, final revision 30 Sep 2007, accepted 20 Nov 2007

Acknowledgements

This research was supported by project grants from the National Health and Medical Research Council (NHMRC; grant ID numbers: 970598 and 981112), Ian Porter Foundation, Woods Family Trust, and a program grant from the Victorian Health Promotion Foundation. M.W. was supported by a Stanley Research Centre Grant. A.W. was supported by an NHMRC Clinical Research Training Fellowship (251750). S.W. was supported by an NHMRC.
References

<table>
<thead>
<tr>
<th>Group</th>
<th>n (M/F)</th>
<th>Age, years: mean (s.d.)</th>
<th>Height, cm: mean (s.d.)</th>
<th>Premorbid IQ, mean (s.d.)</th>
<th>Handedness (R/L/M/U)</th>
<th>Age at onset of psychosis prior to scan, years: mean (s.d.)</th>
<th>Duration of psychosis prior to scan, days: mean (s.d.)</th>
<th>Callosal area, mm²: mean (s.d.)</th>
<th>Callosal length, mm: mean (s.d.)</th>
<th>Callosal thickness, mm: mean (s.d.)</th>
<th>PANSS positive symptoms, mean (s.d.)</th>
<th>PANSS negative symptoms, mean (s.d.)</th>
<th>Chlorpromazine equivalents, mg: mean (s.d.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established schizophrenia</td>
<td>86 (73/13)</td>
<td>34.57 (9.51)</td>
<td>174.21 (7.92)</td>
<td>94.87 (14.47)</td>
<td>71/6/5/4</td>
<td>22.07 (5.93)</td>
<td>4547 (3657)</td>
<td>644.90 (87.48)</td>
<td>105.30 (7.85)</td>
<td>6.78 (0.86)</td>
<td>21.89 (7.03)</td>
<td>23.48 (7.90)</td>
<td>655 (545)</td>
</tr>
<tr>
<td>First-episode psychosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>30 (22/8)</td>
<td>21.56 (3.82)</td>
<td>173.57 (9.93)</td>
<td>91.61 (16.94)</td>
<td>25/4/1/0</td>
<td>21.71 (3.71)</td>
<td>90.57 (115.90)</td>
<td>649.08 (106.48)</td>
<td>101.57 (7.40)</td>
<td>7.06 (0.91)</td>
<td>23.00 (7.63)</td>
<td>240 (249)</td>
<td></td>
</tr>
<tr>
<td>Schizophreniform</td>
<td>31 (2/238)</td>
<td>20.85 (3.31)</td>
<td>174.40 (8.66)</td>
<td>94.98 (9.74)</td>
<td>27/4/0/0</td>
<td>20.72 (3.30)</td>
<td>42.02 (59.80)</td>
<td>648.62 (67.93)</td>
<td>101.35 (7.08)</td>
<td>7.08 (0.69)</td>
<td>21.25 (6.83)</td>
<td>178 (119)</td>
<td></td>
</tr>
<tr>
<td>Schizoaffective</td>
<td>15 (1114)</td>
<td>20.98 (2.97)</td>
<td>171.17 (8.88)</td>
<td>92.24 (14.94)</td>
<td>13/2/0/0</td>
<td>20.91 (2.94)</td>
<td>60.80 (104.99)</td>
<td>693.33 (100.47)</td>
<td>102.35 (6.35)</td>
<td>7.51 (0.97)</td>
<td>20.77 (8.05)</td>
<td>127 (118)</td>
<td></td>
</tr>
<tr>
<td>Group</td>
<td>76 (56/20)</td>
<td>21.15 (3.42)</td>
<td>173.43 (9.18)</td>
<td>92.96 (14.17)</td>
<td>65/10/1/0</td>
<td>21.12 (3.39)</td>
<td>64.20 (112.22)</td>
<td>657.63 (91.82)</td>
<td>101.64 (6.99)</td>
<td>7.23 (1.51)</td>
<td>23.87 (6.48)</td>
<td>21.17 (6.87)</td>
<td>186 (166)</td>
</tr>
<tr>
<td>Controls</td>
<td>55 (34/21)</td>
<td>26.81 (10.59)</td>
<td>174.15 (9.06)</td>
<td>101.77 (10.66)</td>
<td>50/4/1/0</td>
<td>N/A</td>
<td>N/A</td>
<td>656.26 (97.16)</td>
<td>104.45 (16.12)</td>
<td>7.19 (1.09)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

M/F, male/female; N/A, not applicable; R/L/M/U, right/left/mixed/unknown; PANSS, Positive and Negative Syndrome Scale.
Morphology of the corpus callosum at different stages of schizophrenia: cross-sectional study in first-episode and chronic illness


Access the most recent version at DOI: 10.1192/bjp.bp.107.041251